These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16848380)

  • 1. Antihypertensive agents for prevention of diabetic nephropathy.
    Dressler RL
    Am Fam Physician; 2006 Jul; 74(1):77-9. PubMed ID: 16848380
    [No Abstract]   [Full Text] [Related]  

  • 2. Diabetic nephropathy.
    Goto A
    N Engl J Med; 2002 Sep; 347(12):947-8; author reply 947-8. PubMed ID: 12239270
    [No Abstract]   [Full Text] [Related]  

  • 3. [Should normotensive diabetic patients with microalbuminuria be treated with angiotensin converting enzyme inhibitors?].
    Feldt-Rasmussen BF
    Ugeskr Laeger; 2002 Apr; 164(14):1907-9. PubMed ID: 11957423
    [No Abstract]   [Full Text] [Related]  

  • 4. Hypertension arm of ADVANCE defines extent of renal protection using perindopril/indapamide in type 2 diabetics.
    Cardiovasc J Afr; 2008; 19(4):226. PubMed ID: 18776973
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical practice. Nephropathy in patients with type 2 diabetes.
    Remuzzi G; Schieppati A; Ruggenenti P
    N Engl J Med; 2002 Apr; 346(15):1145-51. PubMed ID: 11948275
    [No Abstract]   [Full Text] [Related]  

  • 6. Should Angiotensin converting enzyme inhibitors be used in children with type 1 diabetes and microalbuminuria?
    Almerie MQ; Williams RM; Acerini CL
    Arch Dis Child; 2008 Jul; 93(7):633-5. PubMed ID: 18285389
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical inquiries. Do ACE inhibitors prevent nephropathy in type 2 diabetes without proteinuria?
    Sferra L; Kelsberg G; Dodson S; Saseen J
    J Fam Pract; 2004 Jan; 53(1):68-9. PubMed ID: 14709273
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hypertension therapy for type 2 diabetics].
    Bönner G
    MMW Fortschr Med; 2007 Jun; 149(23):45, 47-8. PubMed ID: 18062579
    [No Abstract]   [Full Text] [Related]  

  • 9. [Revised guidelines for antihypertensive treatment. What is relevant for the general practitioner?].
    Zidek W
    MMW Fortschr Med; 2004 Jan; 146(1-2):37-8. PubMed ID: 18437867
    [No Abstract]   [Full Text] [Related]  

  • 10. FPIN's clinical inquiries. Angiotensin blockade in patients with diabetic nephropathy.
    Jimenez J; Safranek S; Viera AJ
    Am Fam Physician; 2007 Aug; 76(3):423-4. PubMed ID: 17708144
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical inquiries. Does screening for microalbuminuria in diabetes prevent complications?
    Hale WA; Nashelsky J; Wilson SA
    J Fam Pract; 2003 Mar; 52(3):229-31. PubMed ID: 12620179
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical inquiries. Angiotensin blockade for diabetes: monitor microalbuminuria?
    Muench J; Blenning C; Judkins DZ; Vincent C
    J Fam Pract; 2007 Feb; 56(2):145-6. PubMed ID: 17270123
    [No Abstract]   [Full Text] [Related]  

  • 13. Early detection of endothelial dysfunction and early therapeutic correction effectively restore renal function in type 2 diabetic nephropathy.
    Futrakul N; Butthep P
    Ren Fail; 2005; 27(4):493-4. PubMed ID: 16060141
    [No Abstract]   [Full Text] [Related]  

  • 14. Diabetic nephropathy: introduction.
    Breyer MD
    Semin Nephrol; 2007 Mar; 27(2):129. PubMed ID: 17418681
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical studies on chronic diabetic nephropathy and recent data concerning prevention of risks of nephropathy and cardiovascular diseases].
    Esnault V
    Nephrol Ther; 2006 May; 2 Suppl 3():S193-6. PubMed ID: 17370850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating diabetic nephropathy: unfinished success is not failure.
    Lewis J
    Clin J Am Soc Nephrol; 2007 May; 2(3):407-9. PubMed ID: 17699442
    [No Abstract]   [Full Text] [Related]  

  • 17. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CARI guidelines. Cost-effectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes.
    Chadban S; Howell M; Twigg S; Thomas M; Jerums G; Cass A; Campbell D; Nicholls K; Tong A; Mangos G; Stack A; MacIsaac RJ; Girgis S; Colagiuri R; Colagiuri S; Craig J;
    Nephrology (Carlton); 2010 Apr; 15 Suppl 1():S195-203. PubMed ID: 20591031
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiotensin-converting enzyme inhibitors in diabetes: effect on the kidney and on blood pressure.
    Björck S; Aurell M
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S59-63. PubMed ID: 16989067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ambitious American guidelines for control of risk factors in diabetes. Was the aim put too high?].
    Nilsson P; Attvall S; Weiss L
    Lakartidningen; 2003 Jan; 100(1-2):26-30. PubMed ID: 12572133
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.